| Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments EI Nielsen, A Viberg, E Löwdin, O Cars, MO Karlsson, M Sandström Antimicrobial agents and chemotherapy 51 (1), 128-136, 2007 | 199 | 2007 |
| Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats LE Friberg, A Freijs, M Sandström, MO Karlsson Journal of Pharmacology and Experimental Therapeutics 295 (2), 734-740, 2000 | 103 | 2000 |
| Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. M Hassan, A Fasth, B Gerritsen, A Haraldsson, Z Syrůcková, ... Bone marrow transplantation 18 (5), 843-850, 1996 | 102 | 1996 |
| Developmental pharmacokinetics of gentamicin in preterm and term neonates EI Nielsen, M Sandström, PH Honoré, U Ewald, LE Friberg Clinical pharmacokinetics 48 (4), 253-263, 2009 | 96 | 2009 |
| Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients A Henningsson, A Sparreboom, M Sandström, A Freijs, R Larsson, ... European Journal of Cancer 39 (8), 1105-1114, 2003 | 96 | 2003 |
| Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients M Sandström, H Lindman, P Nygren, M Johansson, J Bergh, MO Karlsson Cancer chemotherapy and pharmacology 58 (2), 143-156, 2006 | 90 | 2006 |
| Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients ABMH M Sandström, M O Karlsson, P Ljungman, Z Hassan, E N Jonsson, C Nilsson ... Bone Marrow Transplantation 28 (7), 657-664, 2001 | 90 | 2001 |
| Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients M Sandstrom, H Lindman, P Nygren, E Lidbrink, J Bergh, MO Karlsson Journal of clinical oncology 23 (3), 413-421, 2005 | 81 | 2005 |
| Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. M Sandström, A Freijs, R Larsson, P Nygren, ML Fjällskog, J Bergh, ... Journal of clinical oncology 14 (5), 1581-1588, 1996 | 73 | 1996 |
| Pharmacodynamics and systemic exposure of esomeprazole in preterm infants and term neonates with gastroesophageal reflux disease T Omari, P Lundborg, M Sandström, P Bondarov, M Fjellman, R Haslam, ... The Journal of pediatrics 155 (2), 222-228, 2009 | 65 | 2009 |
| Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model LE Friberg, M Sandström, MO Karlsson Investigational new drugs 28 (6), 744-753, 2010 | 49 | 2010 |
| Pharmacokinetic/pharmacodynamic modelling in oncological drug development MO Karlsson, T Anehall, LE Friberg, A Henningsson, C Kloft, ... Basic & clinical pharmacology & toxicology 96 (3), 206-211, 2005 | 46 | 2005 |
| Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo S Hassan, S Dhar, M Sandström, D Arsenau, M Budnikova, I Lokot, ... Cancer chemotherapy and pharmacology 55 (1), 47-54, 2005 | 42 | 2005 |
| The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic … A Lannergård, A Viberg, O Cars, MO Karlsson, M Sandström, A Larsson Scandinavian journal of infectious diseases 41 (9), 663-671, 2009 | 35 | 2009 |
| A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function A Viberg, A Lannergård, A Larsson, O Cars, MO Karlsson, M Sandström British journal of clinical pharmacology 62 (3), 297-303, 2006 | 35 | 2006 |
| Determination of cefuroxime in human serum or plasma by liquid chromatography with electrospray tandem mass spectrometry A Viberg, M Sandström, B Jansson Rapid communications in mass spectrometry 18 (6), 707-710, 2004 | 31 | 2004 |
| Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression EK Hansson, JE Wallin, H Lindman, M Sandström, MO Karlsson, ... Cancer chemotherapy and pharmacology 65 (5), 839-848, 2010 | 30 | 2010 |
| The pharmacokinetics of epirubicin and docetaxel in combination in rats M Sandström, LE Simonsen, A Freijs, MO Karlsson Cancer chemotherapy and pharmacology 44 (6), 469-474, 1999 | 16 | 1999 |
| Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response JC Earp, N Mehrotra, KE Peters, RP Fiorentino, D Griebel, SC Lee, ... Journal of pediatric gastroenterology and nutrition 65 (3), 272-277, 2017 | 13 | 2017 |
| Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to … M Sandström, G Davidson, V Tolia, JE Sullivan, G Långström, P Lundborg, ... Clinical therapeutics 34 (8), 1828-1838, 2012 | 12 | 2012 |
